MetLife Investment Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

MetLife Investment Management’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-55,182	Closed	-$86.6K	–	2837
2024 Q3	$86.6K	Hold	55,182	–	–	﹤0.01%	2680
2024 Q2	$92.7K	Buy	55,182 +22,320	+68%	+$40K	﹤0.01%	2642
2024 Q1	$78.9K	Buy	+32,862	New	+$70.6K	﹤0.01%	2639
2023 Q4	–	Sell	-42,834	Closed	-$46.7K	–	2850
2023 Q3	$46.7K	Hold	42,834	–	–	﹤0.01%	2837
2023 Q2	$98.1K	Hold	42,834	–	–	﹤0.01%	2691
2023 Q1	$104K	Buy	42,834 +20,999	+96%	+$48.1K	﹤0.01%	2534
2022 Q4	$41.7K	Sell	21,835 -18,221	-45%	-$38.8K	﹤0.01%	2774
2022 Q3	$96.1K	Buy	+40,056	New	+$111K	﹤0.01%	2691
2022 Q1	–	Sell	-25,604	Closed	-$101K	–	2755
2021 Q4	$101K	Hold	25,604	–	–	﹤0.01%	2404
2021 Q3	$123K	Buy	+25,604	New	+$105K	﹤0.01%	2347
2019 Q3	–	Sell	-23,843	Closed	-$150K	–	2365
2019 Q2	$150K	Hold	23,843	–	–	﹤0.01%	2190
2019 Q1	$133K	Hold	23,843	–	–	﹤0.01%	2199
2018 Q4	$158K	Hold	23,843	–	–	﹤0.01%	2039
2018 Q3	$254K	Hold	23,843	–	–	﹤0.01%	1950
2018 Q2	$286K	Hold	23,843	–	–	﹤0.01%	1738
2018 Q1	$204K	Hold	23,843	–	–	﹤0.01%	1882
2017 Q4	$236K	Buy	+23,843	New	+$248K	﹤0.01%	1838

Other funds holding LXRX

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MetLife Investment Management's LXRX Position: Q4 2024 in Review

MetLife Investment Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2024, closing a stake of 55,182 shares — an estimated $86.6K sold.

MetLife Investment Management first reported a position in LXRX in Q4 2017 and held it in 17 quarters. The position peaked at $286K in Q2 2018. 127 funds tracked by Wall St. Rank hold LXRX as of Q4 2024.

MetLife Investment Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
MetLife Investment Management sold 55,182 Lexicon Pharmaceuticals shares in Q4 2024, an estimated $86.6K.
MetLife Investment Management first reported a position in Lexicon Pharmaceuticals in Q4 2017 and held it in 17 quarters.
MetLife Investment Management's Lexicon Pharmaceuticals position peaked at $286K in Q2 2018.
127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2024.

Based on MetLife Investment Management's 13F filing for Q4 2024, filed 13 Feb 2025.